一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2300 | 0.1300 | 76.92 | 0.8600 | | 每股净资产（元） | 0 | 19.32 | -100 | 19.99 | | 每股公积金(元) | 16.07 | 16.41 | -2.07 | 16.33 | | 每股未分配利润(元) | 1.79 | 2.01 | -10.95 | 2.35 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.85 | 1.68 | 10.12 | 2.42 | | 净利润(亿元) | 0.15 | 0.09 | 66.67 | 0.54 | | 净资产收益率(%) | | 0.68 | -100 | 5.04 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 2226.32万股，累计占流通股比： 52.82%，较上期变化： 3 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥31,710,954.27, representing a 20.83% increase compared to ¥26,243,560.85 in the same period last year[3]. - The net profit attributable to shareholders was -¥12,541,274.58, a decrease of 546.94% from a profit of ¥2,806,035.56 in the previous year[3]. - Total operating revenue for Q1 2025 reached ¥31,710,954.27, a 20.5% increase from ¥26,243,560.85 in Q1 2024[15]. - Net profit for Q1 2025 was a loss of ¥12,541,274.58, compared to a profit of ¥2,806,035.56 in Q1 2024[16]. - The company reported a total comprehensive loss of ¥12,538,571.68 in Q1 2025, compared to a comprehensive income of ¥2,805,459.60 in Q1 2024[16]. Cash Flow and Assets - The net cash flow from operating activities was ¥7,385,690.84, a significant improvement from -¥10,799,735.21 in the same period last year[3]. - Cash flow from operating activities generated a net inflow of ¥7,385,690.84 in Q1 2025, contrasting with a net outflow of ¥10,799,735.21 in Q1 2024[18]. - Cash and cash equivalents decreased to CNY 625,007,416.36 from CNY 820,957,686.09, representing a decline of about 23.9%[11]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥622,438,926.36, down from ¥909,183,442.94 at the end of Q1 2024[19]. - The company's current assets totaled CNY 1,081,377,564.08, down from CNY 1,104,629,429.94 in the previous period, indicating a decrease of approximately 2.4%[11]. Expenses and Liabilities - Research and development expenses totaled ¥14,169,628.05, accounting for 44.68% of operating revenue, a slight decrease of 0.46 percentage points from 45.14%[3]. - Total operating costs increased to ¥46,308,457.10 in Q1 2025, up 30.4% from ¥35,537,854.94 in Q1 2024[15]. - Research and development expenses for Q1 2025 were ¥14,169,628.05, an increase of 19.5% from ¥11,845,032.38 in Q1 2024[15]. - The company's total liabilities decreased to CNY 114,226,860.12 from CNY 124,476,625.25, reflecting a reduction of approximately 8.1%[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,792[8]. - The top shareholder, Zhou Maolin, holds 15,727,700 shares, representing 23.59% of the total shares[8]. Asset Changes - The total assets at the end of the reporting period were ¥1,374,436,713.25, a decrease of 1.04% from ¥1,388,824,565.76 at the end of the previous year[3]. - As of March 31, 2025, the total assets of the company amounted to CNY 1,374,436,713.25, a slight decrease from CNY 1,388,824,565.76 at the end of 2024[11]. - The total equity attributable to shareholders was CNY 1,260,209,853.13, slightly down from CNY 1,264,347,940.51, indicating a decrease of about 0.3%[13]. - The company reported a total of CNY 190,000,000.00 in trading financial assets as of March 31, 2025, significantly up from CNY 30,250,000.00 previously, marking an increase of 528.9%[11]. - The inventory increased to CNY 61,896,001.15 from CNY 48,391,587.34, which is an increase of approximately 28.0%[12]. - The company’s accounts receivable slightly increased to CNY 192,446,224.45 from CNY 190,601,345.62, reflecting a growth of about 1.0%[11]. Other Information - The company reported non-recurring gains and losses totaling ¥530,520.34 for the period[5]. - The company has not reported any changes in the participation of major shareholders in financing or securities lending activities[10]. - There are no significant new strategies or product developments mentioned in the current report[10].

Financial Performance - The company's operating revenue for 2024 reached ¥185,316,037.93, representing a 10.14% increase compared to ¥168,250,840.04 in 2023[22]. - Net profit attributable to shareholders for 2024 was ¥15,273,060.85, a significant increase of 69.99% from ¥8,984,430.03 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥8,801,381.74, up 234.99% from ¥2,627,367.16 in 2023[22]. - The main business revenue increased by 10.09% to ¥184,507,474.96, driven by an expansion in sales scale[134]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management and pricing strategies[182]. - The company achieved operating revenue of ¥185,316,037.93 in 2024, representing a year-on-year growth of 10.14%[129]. - The main business cost rose by 21.46% to ¥79,678,446.66, leading to a decrease in gross margin by 4.04 percentage points to 56.82%[134]. Research and Development - The company reported a significant increase in R&D efforts, focusing on new technologies and products to drive future growth[22]. - R&D expenses as a percentage of revenue for 2022, 2023, and 2024 are 25.43%, 30.95%, and 26.57% respectively, highlighting the company's commitment to innovation[34]. - The total R&D investment for the year was CNY 49.24 million, a decrease of 5.45% compared to the previous year[106]. - The company has developed 13 core technologies related to industrial automation and machine vision detection, maintaining their advanced status during the reporting period[96]. - The company has invested 100 million yuan in R&D for new technologies, aiming to innovate its product line and improve service offerings[182]. - The company is committed to enhancing its research and development capabilities and expand its product matrix to include sectors such as semiconductors, biomedical, and new energy[164]. Corporate Governance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[4]. - The company has not disclosed any special arrangements for corporate governance[5]. - The company has established specialized committees within the board, including an Audit Committee and a Strategic Committee, to enhance governance[197]. - The board held a total of 12 meetings this year, with 8 conducted in a hybrid format combining in-person and remote participation[195]. - The company has implemented a comprehensive internal control system to ensure compliance, asset security, and the integrity of financial reporting, promoting sustainable development[174]. - The company has appointed new independent directors, enhancing its governance structure[181]. Market Strategy and Expansion - The company aims to improve its market position through strategic mergers and acquisitions, as evidenced by the recent acquisition activity[13]. - The company plans to deepen its focus on the consumer electronics sector while diversifying its business into various downstream application industries[164]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[182]. - Market expansion plans include entering two new international markets by Q3 2024, projected to increase market share by 5%[184]. - The company is considering strategic acquisitions to bolster its technology portfolio, with a budget of 300 million RMB allocated for potential deals[186]. Risk Management - The company has detailed various risk factors in its management discussion and analysis section, which investors should be aware of[3]. - The company faces risks related to intensified competition in the modular testing instrument sector, necessitating timely updates to technology and product innovation[127]. - The company has confirmed that all directors attended the board meeting[4]. - The company has not violated any decision-making procedures regarding external guarantees[7]. - The company has established stable business relationships with major consumer electronics companies, enhancing product quality and efficiency[117]. Employee and Compensation - The company has implemented an employee stock ownership plan to align the interests of shareholders, the company, and employees, enhancing team cohesion and competitiveness[38]. - Total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 521.39 million yuan[188]. - Total remuneration for core technical personnel at the end of the reporting period was 383.83 million yuan[188]. - The number of R&D personnel increased to 181, accounting for 60.74% of the total workforce, up from 53.19% in the previous period[113]. - The average salary for R&D personnel decreased slightly to 25.83 million from 26.20 million[113]. Product Development and Innovation - The company has developed its own modular instrument platform named NYSA, enhancing its product offerings[13]. - The company focuses on precision measurement, high-speed signal measurement, and RF testing in its new product development, aiming to meet diverse customer needs[36]. - The modular instruments developed by the company integrate advanced software and measurement technologies, enhancing user configuration and maintenance capabilities while reducing hardware replacement costs[76]. - The company has developed a digital audio interface technology that utilizes FPGA to implement various digital audio interfaces, enhancing signal collection capabilities[99]. - The company is committed to enhancing its product offerings through continuous innovation in embedded systems and automation technologies[100]. Financial Strategy - The company plans to use part of its temporarily idle funds for cash management as approved in the board meeting on March 27, 2024[192]. - The company plans to raise matching funds, with details on the amount and intended use of these funds outlined in the proposal[193]. - The company has submitted a rectification report following the regulatory measures taken by the CSRC[190]. - The company is in the process of revising its governance documents, including the Articles of Association and various committee work rules[192]. - The company approved a proposal for issuing shares and cash to acquire assets and raise matching funds, indicating a strategic move for growth[193].

| | | | 一、审计报告……………………………………………………… 第 1—5 页 | | --- | | 二、财务报表……………………………………………………… 第 6—13 页 | | （一）合并资产负债表…………………………………………… 第 6 页 | | （二）母公司资产负债表………………………………………… 第 7 页 | | （三）合并利润表………………………………………………… 第 8 页 | | （四）母公司利润表……………………………………………… 第 9 页 | | （五）合并现金流量表……………………………………………第 10 页 | | （六）母公司现金流量表…………………………………………第 11 页 | | （七）合并所有者权益变动表……………………………………第 12 页 | | （八）母公司所有者权益变动表…………………………………第 13 页 | | | | | | | 审 计 报 告 天健审〔2025〕7-528 号 广州思林杰科技股份有限公司全体股东： 一、审计意见 我们审计了广州思林杰科技股份有限公司（以下简称思林杰公司）财务报表， 包括 2024 年 12 月 ...

2024 年度募集资金存放和实际使用情况的核查意见 民生证券股份有限公司（以下简称"保荐机构"）作为广州思林杰科技股份有 限公司（以下简称"思林杰"或"公司"）首次公开发行股份并在科创板上市的保荐 机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上 市规则》等有关规定等有关法律法规和规范性文件的要求，保荐机构对思林杰 2024 年度募集资金存放与实际使用情况的事项进行了专项核查，并发表如下意 见： 一、持续督导工作情况 中国证券监督管理委员会于 2022 年 1 月 18 日核发《关于同意广州思林杰科 技股份有限公司首次公开发行股票注册的批复》证监许可〔2022〕130 号。公司 于 2022 年 3 月 14 日在上海证券交易所首次公开发行人民币普通股（A 股）1,667 万股并上市。本次发行募集资金总额 109,438.55 万元，全部为公司公开发行新股 募集，扣除发行费用（不含增值税）人民币 11,889.44 万元后，募集资金净额为 97,549.11 万元。募集资金已由民生证券股份有限公司于 2022 年 3 月 9 日汇入公 司募集资金监管户。天健会计师事务所（特殊普通合伙）对 ...

目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 二、关于募集资金年度存放与使用情况的专项报告…………… 第 3—12 页 三、资格证书复印件………………………………………………第 13—16 页 募集资金年度存放与使用情况鉴证报告 天健审〔2025〕7-530 号 广州思林杰科技股份有限公司全体股东： 我们鉴证了后附的广州思林杰科技股份有限公司（以下简称思林杰公司）管 理层编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供思林杰公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为思林杰公司年度报告的必备文件，随同其他文件一起 报送并对外披露。 二、管理层的责任 思林杰公司管理层的责任是提供真实、合法、完整的相关资料，按照《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修 订）》（证监会公告〔2022〕15 号）和《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作（2023 年 12 月修订）》（上证发〔2023〕194 号） 的规定编制《关 ...

民生证券股份有限公司 关于广州思林杰科技股份有限公司 2024 年持续督导跟踪报告 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为广州 思林杰科技股份有限公司（以下简称"思林杰"或"公司"）持续督导工作的保 荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票 上市规则》等有关法律法规和规范性文件的要求，对思林杰进行持续督导，持续 督导期为 2022 年 3 月 14 日至 2025 年 12 月 31 日。民生证券通过日常沟通、定 期回访、现场检查、尽职调查等方式进行持续督导，现就 2024 年持续督导工作 报告如下： 1 序号 工作内容 实施情况 1 建立健全并有效执行持续督导工作制 度，并针对具体的持续督导工作制定相 应的工作计划 保荐机构已建立健全并有效执行了持续督导 制度，并制定了相应的工作计划 2 根据中国证监会相关规定，在持续督导 工作开始前，与上市公司签署持续督导 协议，明确双方在持续督导期间的权利 义务，并报上海证券交易所备案 保荐机构已与思林杰签订承销及保荐协议，该 协议明确了双方在持续督导期间的权利和义 务 3 持续督导期间，按照有关规定对上市公 司违法 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 | | | 二、非经营性资金占用及其他关联资金往来情况汇总表…………第 3—3 页 三、资格证书复印件…………………………………………………第 4—7 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕7-531 号 广州思林杰科技股份有限公司全体股东： 我们接受委托，审计了广州思林杰科技股份有限公司（以下简称思林杰公司） 2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们审计了后 附的思林杰公司管理层编制的 2024 年度《非经营性资金占用及其他关联资金往 来情况汇总表》（以下简称汇总表）。 一、对报告使用者和使用目的的限定 本报告仅供思林杰公司年度报告披露时使用，不得用作任何其他目的。我们 同意将本报告作为思林杰公司年度报告的必备文件，随同其他文件一起报送并对 外披露。 为了更好地理解思林杰公司 2024 年度非经营性资金占用及其他关联资金往 ...

目 录 | 页 | | --- | | 一、内部控制审计报告………………………………………………第 1—2 | | | | 内部控制审计报告 天健审〔2025〕7-529 号 广州思林杰科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了广州思林杰科技股份有限公司（以下简称思林杰公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是思林 杰公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，思林杰公司于 2 ...

目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 二、关于募集资金年度存放与使用情况的专项报告…………… 第 3—12 页 三、资格证书复印件………………………………………………第 13—16 页 募集资金年度存放与使用情况鉴证报告 天健审〔2025〕7-530 号 广州思林杰科技股份有限公司全体股东： 我们鉴证了后附的广州思林杰科技股份有限公司（以下简称思林杰公司）管 理层编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供思林杰公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为思林杰公司年度报告的必备文件，随同其他文件一起 报送并对外披露。 二、管理层的责任 思林杰公司管理层的责任是提供真实、合法、完整的相关资料，按照《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修 订）》（证监会公告〔2022〕15 号）和《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作（2023 年 12 月修订）》（上证发〔2023〕194 号） 的规定编制《关 ...